INCY Incyte Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: INCY

Price (delayed)

$116.86

Market cap

$23.35B

P/E Ratio

16.03

Dividend/share

N/A

EPS

$7.29

Enterprise value

$19.92B

?
Relative Growth: Rel. Growth: 97
Relative Strength: Rel. Strength: 77
Relative Valuation: Rel. Valuation: 86
Relative Profitability: Rel. Profitability: 99

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug, ...

Highlights
The company's quick ratio has surged by 81% YoY and by 12% QoQ
INCY's equity has surged by 53% year-on-year and by 9% since the previous quarter
INCY's P/E is 80% below its 5-year quarterly average of 81.9 but 12% above its last 4 quarters average of 14.3
Sector: Healthcare
Industry: Biotechnology
Website: https://www.incyte.com/
Peers: AMGN LGND PFE LLY

Key stats

What are the main financial stats of INCY

INCY stock price

How has the Incyte stock price performed over time
Intraday
2.68%
1 week
8.68%
1 month
26.69%
1 year
71.42%
YTD
18.32%
QTD
3.09%

Financial performance

How have Incyte's revenue and profit performed over time
Revenue
$5.36B
Gross profit
$4.96B
Operating income
$1.61B
Net income
$1.43B
Gross margin
92.5%
Net margin
26.7%
Incyte's revenue has increased by 21% YoY and by 4.3% from the previous quarter
INCY's gross profit is up by 21% year-on-year and by 4% since the previous quarter
INCY's net income is up by 11% since the previous quarter
The net margin is up by 7% since the previous quarter

Price vs fundamentals

How does INCY's price correlate with its fundamentals

Growth

What is Incyte's growth rate over time

Valuation

What is Incyte stock price valuation
INCY P/E details
P/E
16.03
P/B
4.14
P/S
4.35
EV/EBIT
11.21
EV/EBITDA
10.65
EV/Sales
3.72
INCY's P/E is 80% below its 5-year quarterly average of 81.9 but 12% above its last 4 quarters average of 14.3
INCY's EPS is up by 11% QoQ
INCY's equity has surged by 53% year-on-year and by 9% since the previous quarter
The stock's price to book (P/B) is 18% more than its last 4 quarters average of 3.5 and 15% more than its 5-year quarterly average of 3.6
INCY's P/S is 28% above its last 4 quarters average of 3.4 and 9% above its 5-year quarterly average of 4.0
Incyte's revenue has increased by 21% YoY and by 4.3% from the previous quarter

Efficiency

How efficient is Incyte business performance
INCY's return on assets is up by 4.8% since the previous quarter
The ROIC has increased by 2.8% from the previous quarter
INCY's ROS is up by 2.2% QoQ

Dividends

What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INCY.

Financial health

How did Incyte financials performed over time
The company's quick ratio has surged by 81% YoY and by 12% QoQ
The current ratio has soared by 80% YoY and by 11% from the previous quarter
The debt is 99% smaller than the equity
INCY's equity has surged by 53% year-on-year and by 9% since the previous quarter
The debt is down by 9% year-on-year and by 2.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.